Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2017 June;69(3) > Minerva Ginecologica 2017 June;69(3):245-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Minerva Ginecologica 2017 June;69(3):245-9

DOI: 10.23736/S0026-4784.17.04015-1

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Efficacy and tolerability of a plant-based, multi-component cream (Ginetrox®) in vulvovaginal disorders of the genitourinary syndrome during menopause

Roberto MARRAI 1, Giovanni LISSI 2, Stefano TOGNI 3, Giada MARAMALDI 3, Marco BARBARA 4, Luca GIACOMELLI 5

1 Obstetrics and Gynecology Unit, G. Pasquinucci Hospital, Massa, Italy; 2 Funziona Srl, Milan, Italy; 3 Indena SpA, Milan, Italy; 4 University of Palermo, Palermo, Italy; 5 Department of Surgical Sciences and Integrated Diagnostics, School of Medicine, University of Genoa, Genoa, Italy


PDF


BACKGROUND: Genitourinary syndrome of menopause (GSM) is a symptomatic condition including vaginal dryness, irritation, dyspareunia and recurrent urinary tract infections which affects 40-54% of post-menopausal women. Although several estrogen-based therapies are available, it is generally preferable to avoid hormonal therapy, particularly in women with mild symptoms or at risk for estrogen-responsive neoplasia. Therefore, the most common treatment options are over-the-counter vaginal creams for symptomatic relief.
METHODS: Thirty-three postmenopausal women suffering from GSM were enrolled in this observational study. A multi-component cream (Ginetrox®, Indena, Milan, Italy) was applied on the vestibular area of the vagina for three months. The primary endpoints were: vaginal burning and/or pain, assessed by Visual Analog Scale and dyspareunia, assessed using the Marinoff Score. As a secondary endpoint, vestibular health was evaluated through a four-point scale. Side effects and adherence to treatment were also recorded.
RESULTS: Statistically significant improvement was observed in pain scores and dyspareunia at the end of the treatment compared to baseline values. The vestibular health index significantly decreased after 3 months. Tolerability was acceptable.
CONCLUSIONS: This preliminary study suggests that the plant-based, multi-component cream Ginetrox® could be effective and safe in counteracting menopause-related vaginal discomfort symptoms.


KEY WORDS: Female urogenital diseases - Menopause - Vaginal creams, foams, and jellies - Dyspareunia - Tamarindus - Madecassoside

top of page